Formulary E-news :
Having trouble viewing this e-mail? Click here. 		You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Formulary E-news
Modern Medicine Network
 
 
 
 
 
TOP SEARCHES: REMS// Rheumatoid arthritis // Pain
In this issue
• Antibiotic push in 2010
• FDA approval time
• Fertility drugs
• Statin use and gallstones
Key Topic Updates

Survey

This month we would like to know...

In light of increased government funding and focus in the area of comparative effectiveness research, which therapeutic area do you feel ranks highest in terms of need for such research?

a) cardiology (e.g., CAD, hypertension)
   
b) endocrinology (e.g., diabetes)
   
c) mental health (e.g., depression, schizophrenia)
   
d) oncology
   
e) allergy/pulmonology (e.g., asthma, COPD)
   

Vote in our survey, and see what other P&T committee members have to say.
Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

DECEMBER 11 , 2009
IDSA requests 10 new antibiotics by 2020
The Infectious Diseases Society of America (IDSA) is calling for development of 10 new antibiotics by 2020. More...
No change in FDA approval time despite new technology, study shows
Even given implementation of information technology, FDA drug approval time has not decreased, according to researchers. More...
Some fertility drugs pose slight risk of cancer, based on duration of use
Use of fertility drugs does not seem to generally increase uterine cancer risk, however, a Danish study identified small increases in risk from certain fertility drugs used for a longer period. More...
Statin use lowers risk of gallstones followed by cholecystectomy
Use of statins over a long period of time was associated with a decreased risk of gallstones followed by cholecystectomy. More...
Key Topic Updates
FDA Approvals
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
FDA actions in brief, November 2009 (FluMist, Cervarix, Gardasil, Fluarix, Folotyn, Micardis, Twynsta, Votrient, Mirena)
Valsartan and aliskiren (Valturna): Combination of an angiotensin receptor blocker with direct renin inhibitor approved for the treatment of hypertension
Medication Safety
Thiopurines increase lymphoproliferative disorder risk in IBD patients
Bloodstream infections and contaminated prefilled syringes: issues of medication safety
Two antimalaria drugs are tolerated regimens in regions with resistance
Regulatory/Legislative
Safety concerns slow new drug review and approval processes
FDA leadership promotes scientific integrity, quality standards
Global health concerns generate new therapies for home and abroad

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.